AstraZeneca stock falls after FDA panel votes against new cancer drug
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival rates.
AstraZeneca stock falls after FDA panel votes against new cancer drug basliginda one cikan gelisme: The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival rates.
Fonvera editor notu: Haberin piyasa etkisini izlemek icin ilgili varlik sayfalari ve ekonomik takvim akisi birlikte okunmalidir.